Guangzhou Viro-Bio

Guangzhou Viro-Bio Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation oncolytic virus therapies and mRNA-based drugs. As a core subsidiary of Virogin Biotech, the company leverages its proprietary Synerlytic platform to engineer oncolytic Herpes Simplex Virus (oHSV-1) candidates designed to enhance systemic anti-tumor immunity. The company's lead candidate, VG161, is an armed oncolytic virus that expresses multiple immune-stimulating payloads and is currently in Phase 2 clinical trials for solid tumors such as hepatocellular carcinoma. Guangzhou Viro-Bio maintains a state-of-the-art GMP manufacturing facility in Guangzhou, supporting the production of clinical-grade viral vectors and vaccines. The firm's research strategy focuses on combining direct viral oncolysis with localized immunotherapy to overcome the immunosuppressive tumor microenvironment. Backed by top-tier venture capital firms, the company operates with a global footprint, integrating R&D efforts across China and North America.